Literature DB >> 8188350

Toxicity of lipopolysaccharide and of soluble extracts of Salmonella typhimurium in mice immunized with a live attenuated aroA salmonella vaccine.

P Mastroeni1, B Villarreal-Ramos, J A Harrison, R Demarco de Hormaeche, C E Hormaeche.   

Abstract

Mice immunized intravenously 10 days earlier (but not those immunized 2 months earlier) with an attenuated Salmonella typhimurium SL3261 aroA live vaccine and tested for delayed-type hypersensitivity by injection of crude Salmonella extracts in the footpad can die within 24 to 48 h of an unexplained allergic reaction. The lethal reaction could be prevented by prior administration of anti-tumor necrosis factor alpha serum. Injection of lipopolysaccharide (LPS) (either purified phenol-water-extracted [Westphal] LPS or protein-rich trichloracetic acid-extracted [Boivin] LPS) was also lethal for mice immunized 10 days before. An LPS-rich crude Salmonella extract was more toxic than one which contained less LPS, suggesting that LPS may have been involved in the lethal reactions to crude antigens. Mild alkaline hydrolysis removes O-linked acyl groups from lipid A and eliminates many toxic effects of LPS; however, both Boivin LPS and Westphal LPS remained toxic for immunized mice after alkaline hydrolysis. In contrast, alkaline hydrolysis of crude whole Salmonella extracts (which caused marked protein degradation) reduced the lethal toxicity of the extracts, especially for an LPS-rich preparation. Mice immunized orally with the live vaccine did not show hypersensitivity to either LPS or crude extracts. The results suggest that the lethal reaction to crude Salmonella antigens in mice immunized 10 days earlier is complex, that tumor necrosis factor alpha is involved, and that allergic reactions to crude antigens (but not to LPS alone) can be reduced by mild alkaline hydrolysis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8188350      PMCID: PMC186509          DOI: 10.1128/iai.62.6.2285-2288.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  [Immunochemical study on Salmonella. VIII. Role of O acetyl groupings in the specificity of the O:5 factor].

Authors:  K KOTELKO; A M STAUB; R TINELLI
Journal:  Ann Inst Pasteur (Paris)       Date:  1961-05

2.  Delayed hypersensitivity and arthus reactivity in relation to host resistance in salmonella-infected mice.

Authors:  F M Collins; G B Mackaness
Journal:  J Immunol       Date:  1968-11       Impact factor: 5.422

3.  Induction of hypersensitivity to endotoxin and tumor necrosis factor by sublethal infection with Salmonella typhimurium.

Authors:  M Matsuura; C Galanos
Journal:  Infect Immun       Date:  1990-04       Impact factor: 3.441

4.  Differences in delayed-type hypersensitivity responses in various mouse strains in the C3H lineage infected with Salmonella typhimurium, strain SL3235.

Authors:  L M Killar; T K Eisenstein
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

5.  Role of the physical state of Salmonella lipopolysaccharide in expression of biological and endotoxic properties.

Authors:  A Shnyra; K Hultenby; A A Lindberg
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

6.  Serum TNF alpha in mouse typhoid and enhancement of a Salmonella infection by anti-TNF alpha antibodies.

Authors:  P Mastroeni; A Arena; G B Costa; M C Liberto; L Bonina; C E Hormaeche
Journal:  Microb Pathog       Date:  1991-07       Impact factor: 3.738

7.  Release of cytokines induced by Salmonella typhimurium porins.

Authors:  F Galdiero; G C de L'ero; N Benedetto; M Galdiero; M A Tufano
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

8.  Immunity conferred by Aro- Salmonella live vaccines.

Authors:  C E Hormaeche; H S Joysey; L Desilva; M Izhar; B A Stocker
Journal:  Microb Pathog       Date:  1991-02       Impact factor: 3.738

9.  Proliferative and T-cell specific interleukin (IL-2/IL-4) production responses in spleen cells from mice vaccinated with aroA live attenuated Salmonella vaccines.

Authors:  B Villarreal; P Mastroeni; R D de Hormaeche; C E Hormaeche
Journal:  Microb Pathog       Date:  1992-10       Impact factor: 3.738

10.  Endotoxin protein: a B-cell mitogen and polyclonal activator of C3H/HeJ lymphocytes.

Authors:  B M Sultzer; G W Goodman
Journal:  J Exp Med       Date:  1976-09-01       Impact factor: 14.307

View more
  5 in total

1.  Enhanced immunoglobulin A response and protection against Salmonella enterica serovar typhimurium in the absence of the substance P receptor.

Authors:  Nancy Walters; Theresa Trunkle; Michael Sura; David W Pascual
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

2.  Intracellular adhesion molecule 1 plays a key role in acquired immunity to salmonellosis.

Authors:  Simon Clare; Robert Goldin; Christine Hale; Richard Aspinall; Cameron Simmons; Pietro Mastroeni; Gordon Dougan
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

3.  Antigen-encapsulating host extracellular vesicles derived from Salmonella-infected cells stimulate pathogen-specific Th1-type responses in vivo.

Authors:  Winnie W Hui; Lisa E Emerson; Beata Clapp; Austin E Sheppe; Jatin Sharma; Johanna Del Castillo; Mark Ou; Gustavo H B Maegawa; Carol Hoffman; Joseph Larkin Iii; David W Pascual; Mariola J Edelmann
Journal:  PLoS Pathog       Date:  2021-05-06       Impact factor: 6.823

Review 4.  Treatment alternatives of slaughterhouse wastes, and their effect on the inactivation of different pathogens: a review.

Authors:  Ingrid H Franke-Whittle; Heribert Insam
Journal:  Crit Rev Microbiol       Date:  2012-06-13       Impact factor: 7.624

5.  Interleukin-12 is required for control of the growth of attenuated aromatic-compound-dependent salmonellae in BALB/c mice: role of gamma interferon and macrophage activation.

Authors:  P Mastroeni; J A Harrison; J H Robinson; S Clare; S Khan; D J Maskell; G Dougan; C E Hormaeche
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.